Tiotropium + Olodaterol Fixed-Dose Combination Therapy Provides Lung-Function Benefits Compared With Tiotropium Alone In Patients With GOLD A/B And C/D Chronic Obstructive Pulmona…

Rationale: Tiotropium plus olodaterol (T+O) fixed-dose combination therapy combines the long-acting muscarinic antagonist tiotropium and the recently approved long-acting β2-agonist olodaterol as once-daily maintenance treatment in chronic obstructive pulmonary disease (COPD). We present post hoc analyses of data from the two pivotal 1-year TONADO studies that examined the lung-function benefits of T+O 5/5 µg (via Respimat®) compared with T 5 µg (Respimat®) in patients with COPD classified by the Global initiative for chronic Obstructive Lung Disease (GOLD) as A/B and C/D. Methods: Classification as GOLD A/B and…